Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology,Heart Failure Society of America and Japanese Heart Failure Society |
| |
| Affiliation: | 1. Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan;2. Research and Innovation-Nursing Institute, Kaufman Center for Heart Failure-Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA;3. University of Warwick, Warwick, UK, and Monash University, Clayton, Australia;4. Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies; German Centre for Cardiovascular Research partner site Berlin, Germany; Charité Universitätsmedizin Berlin, Germany;5. Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland;6. Heart Institute, Hospital Germans Trias i Pujol, CIBERCV, Badalona, Spain;7. Universitat Autonoma Barcelona, Spain;8. Baylor Scott and White Research Institute, Dallas, Texas, USA;9. University of Mississippi, Jackson, Mississippi, USA;10. Emergency Institute for Cardiovascular Diseases Prof. C.C. Iliescu Bucharest, University of Medicine Carol Davila, Bucharest, Romania;11. Inova Heart and Vascular Institute, Falls Church, Virginia, USA;12. Clinical Chief of Cardiology, University of Texas Southwestern Medical Center, Department of Internal Medicine/Division of Cardiology, Dallas, Texas, USA;13. Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA;14. School of Medicine of National and Kapodistrian University of Athens, Athens University Hospital Attikon, Athens, Greece;15. Massachusetts General Hospital, Harvard Medical School and Baim Institute for Clinical Research, Boston, Massachusetts, USA;16. Second Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan;17. Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan;18. Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan;19. Duke Clinical Research Institute, Durham, Nortth Carolina, USA;20. Cardiology. ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy;21. Division of Cardiology, Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA;22. Centre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy;23. Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan;24. Nara Prefecture Seiwa Medical Center, Sango, Japan;25. Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan;26. Department of Cardiovascular Medicine, Kawaguchi Cardiovascular and Respiratory Hospital, Kawaguchi, Japan;27. University of Belgrade Faculty of Medicine, Serbian Academy of Sciences and Arts, and Heart Failure Center, Belgrade University Medical Center, Belgrade, Serbia;28. Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, California, USA;29. Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Yonago, Japan;30. Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan;2. Department of Advanced Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan;3. Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan;1. Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL;2. Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC;1. Instituto Nacional de Cardiología Ignacio Chávez, Coronary Care Unit, /Ciudad De México, México;2. Instituto Nacional de Cardiología Ignacio Chávez, Interventional Cardiology, Ciudad De México;3. Advanced Heart Failure and Recovery Program for Central Texas, Baylor Scott & White Health, Round Rock, TX, USA;1. Lifespan Cardiovascular Institute, Warren Alpert Medical School of Brown University, Providence, Rhode Island;2. Cardiovascular Institute at Allegheny Health Network, Pittsburgh, Pennsylvania;1. Division of Cardiovascular Medicine, Knight Cardiovascular Institute, Oregon Health and Science University, Portland;2. Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania |
| |
| Abstract: | Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of heart failure (HF). In addition, they can have an important complementary role in the risk stratification of its prognosis. Since the development of angiotensin receptor neprilysin inhibitors (ARNIs), the use of natriuretic peptides as therapeutic agents has grown in importance. The present document is the result of the Trilateral Cooperation Project among the Heart Failure Association of the European Society of Cardiology, the Heart Failure Society of America and the Japanese Heart Failure Society. It represents an expert consensus that aims to provide a comprehensive, up-to-date perspective on natriuretic peptides in the diagnosis and management of HF, with a focus on the following main issues: (1) history and basic research: discovery, production and cardiovascular protection; (2) diagnostic and prognostic biomarkers: acute HF, chronic HF, inclusion/endpoint in clinical trials, and natriuretic peptides-guided therapy; (3) therapeutic use: nesiritide (BNP), carperitide (ANP) and ARNIs; and (4) gaps in knowledge and future directions. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
